Amidst projections for Scala's impact on Nobel Biocare's 2007 growth forecast and operating margin target, JP Morgan anticipates a potential decrease from the current guidance of 23-25 pct to uncertain levels, with the operating margin target also at risk of declining from the current 34-35 pct. The market sentiment reflects apprehension as uncertainties loom over Nobel Biocare's performance in the coming year, prompting cautious anticipation among investors and analysts.